163 related articles for article (PubMed ID: 37269960)
1. Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics.
Patrick S; Lathoria K; Suri V; Sen E
Cell Signal; 2023 Sep; 109():110738. PubMed ID: 37269960
[TBL] [Abstract][Full Text] [Related]
2. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
3. YAP1-mediated regulation of mitochondrial dynamics in IDH1 mutant gliomas.
Patrick S; Gowda P; Lathoria K; Suri V; Sen E
J Cell Sci; 2021 Nov; 134(22):. PubMed ID: 34651186
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
5. Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip.
Cui H; Sun X; Schilling M; Herold-Mende C; Reischl M; Levkin PA; Popova AA; Turcan Ş
Adv Healthc Mater; 2023 Sep; 12(24):e2300591. PubMed ID: 37162029
[TBL] [Abstract][Full Text] [Related]
6. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
7. Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2-β-Catenin-BRG1 Transcriptional Network-Driven CD47 Expression.
Gowda P; Patrick S; Singh A; Sheikh T; Sen E
Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463646
[TBL] [Abstract][Full Text] [Related]
8. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence.
Guichet PO; Masliantsev K; Tachon G; Petropoulos C; Godet J; Larrieu D; Milin S; Wager M; Karayan-Tapon L
J Pathol; 2018 Oct; 246(2):205-216. PubMed ID: 30009411
[TBL] [Abstract][Full Text] [Related]
9. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
10. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ZEB1 and YAP1 is related to poor prognosis in patients with gliomas with different IDH1 status.
Miao N; Wang ZQ; Zhang N; Ma ZP; Su LP; Zhai YY; Hu YR; Sang W; Zhang W
Int J Clin Exp Pathol; 2023; 16(7):138-149. PubMed ID: 37559682
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
[TBL] [Abstract][Full Text] [Related]
13. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP
Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978
[No Abstract] [Full Text] [Related]
14. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
15. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
[TBL] [Abstract][Full Text] [Related]
16. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Ohba S; Mukherjee J; See WL; Pieper RO
Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
[TBL] [Abstract][Full Text] [Related]
17. High levels of TIMP1 are associated with increased extracellular matrix stiffness in isocitrate dehydrogenase 1-wild type gliomas.
Luo CH; Shi Y; Liu YQ; Liu Q; Mao M; Luo M; Yang KD; Wang WY; Chen C; Niu Q; Yan ZX; Miao JY; Zhang XN; Zeng H; Li L; Bian XW; Ping YF
Lab Invest; 2022 Dec; 102(12):1304-1313. PubMed ID: 35882906
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
[TBL] [Abstract][Full Text] [Related]
19. CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
Wang S; Wu J; Zhao W; Li M; Li S
FASEB J; 2023 Apr; 37(4):e22848. PubMed ID: 36906285
[TBL] [Abstract][Full Text] [Related]
20. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]